GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
NCT05194735 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect82/100
StatusTERMINATED
PhasePHASE1 / PHASE2
Lead sponsorAlaunos Therapeutics
Last update2026-11-09
Public-record facts
| Intervention | Neoantigen specific TCR-T cell drug product (BIOLOGICAL), Aldesleukin (IL-2) (BIOLOGICAL) |
|---|---|
| Condition | Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer |
| Enrollment | 8 |
| Why stopped | Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell manufacturing. The study was not stopped for safety reasons. |
| Results posted | Yes |
Why Beacon surfaced it
- The record is terminated and was updated 2026-11-09.
- It is an interventional PHASE1/PHASE2 study with a named biological/biological intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
- ClinicalTrials.gov indicates posted results are available.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT05194735. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.